|Calculated MW||26625 Da|
|Other Names||Tumor necrosis factor ligand superfamily member 9, 4-1BB ligand, 4-1BBL, TNFSF9|
|Target/Specificity||A synthetic peptide corresponding to residues near the N-terminus of human 4-1BBL was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||4-1BBL Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Cytokine that binds to TNFRSF9. Induces the proliferation of activated peripheral blood T-cells. May have a role in activation-induced cell death (AICD). May play a role in cognate interactions between T-cells and B-cells/macrophages.|
|Cellular Location||Membrane; Single-pass type II membrane protein|
|Tissue Location||Expressed in brain, placenta, lung, skeletal muscle and kidney|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
4-1BB was originally described as a cDNA expressed by activated murine T cells and subsequently demonstrated to encode a member of the tumor necrosis factor receptor family of integral membrane proteins. Recently, a murine ligand for 4-1BB (mu4-1BB-L) was cloned and demonstrated to be a member of an emerging family of ligands with structural homology to tumor necrosis factor. Both monoclonal antibody to hu4-1BB and cells transfected with hu4-1BB-L induced a strong proliferative response in mitogen co-stimulated primary T cells. In contrast, ligation of 4-1BB on T cell clones enhanced activation-induced cell death when triggered by engagement of the TCR/CD3 complex. (1). To reject tumors, T cells must overcome poor tumor immunogenicity and an adverse tumor microenvironment. It has been shown that primary human T cells expressing CD80 and 4-1BBL vigorously respond to tumor cells lacking costimulatory ligands and provoke potent rejection of large, systemic tumors in immunodeficient mice (2).
1. Alderson MR, et al. Eur J Immunol 24(9):2219-27, 1994
2. Steohan MT, et al. Nat Med 13(12):1440-9, 2007
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.